Healthcare
Live Price
Offline$1.83
+4.57% today
1Y Change
+201.98%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProKidney Corp. (PROK) is a Healthcare stock with a market cap of $560.00M and listed on NASDAQ. The stock last traded around $1.83 and up 202.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +1075.0%, EPS growth of +16.1%, a dividend yield of 0.0%. What stands out right now is revenue +1075.0%, EPS +16.1%, free cash flow +13.2% with operating margin -18477.8% and ROIC -54.1%. Valuation already assumes a fairly strong business story at price/sales 625.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PROK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PROK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PROK Max Drawdown
-70.08%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PROK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$55.1M
+49.0% YoY
Free Cash Flow
-$55.5M
+29.7% YoY
Revenue Growth
+1075.0%
EPS Growth
+16.1%
Gross Margin
-218.8%
Net Margin
-7725.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 893K | 76K | 0 | 0 | 0 |
| Gross Profit | -5M | 76K | 0 | 0 | 0 |
| Operating Income | -165M | -184M | -152M | -153M | -55M |
| EBITDA | -159M | -158M | -126M | -144M | -53M |
| Net Income | -69M | -61M | -35M | -108M | -55M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 109M | 99M | 61M | 490M | 21M |
| Total Assets | 336M | 441M | 421M | 518M | 40M |
| Total Liabilities | 35M | 39M | 29M | 13M | 13M |
| Shareholder Equity | -1.0B | -995M | -1.1B | -1.1B | 27M |
| Total Debt | 3M | 3M | 4M | 2M | 1M |
| Net Debt | -106M | -96M | -56M | -488M | -19M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
50M
+34.8% YoY
Capital Expenditures
5M
-181.3% YoY
Free Cash Flow
55M
+29.7% YoY
Key ratios
Gross Margin
-218.8%
Operating Margin
-18477.8%
Net Margin
-7725.2%
ROE
6.9%
Debt / Equity
-0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.